1161 – Gefitinib first line testing for mutations of epidermal growth factor receptor (EGFR) in patients with metastatic non-small cell lung cancer

-

This application seeks to extend availability of a test already funded on the MBS for use of gefitinib for first-line treatment in patients with locally advanced or metastatic NSCLC.

There are three histological defined subgroups of NSCLC: (i) adenocarcinoma – often found in an outer area of the lung; (ii) squamous cell carcinoma – usually found in the centre of the lung by an air tube (bronchus); and (iii) large cell carcinoma – may occur in any part of the lung which tends to grow and spread faster than the other two types.

Regardless of the subgroup, NSCLC arises as a consequence of either acquired (somatic) and/or inherited (germ-line) mutations.

• PASC meeting: 
  • 7 July 2011
  • 14 - 15 September 2011
• ESC meeting: 
  • 11 - 12 October 2012
• MSAC meeting: 
  • 29 - 30 November 2012
  • 1 August 2013
  • 24-25 November 2016